Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: December 2, 2009

Drug Name Review Type Class Manufacturer
Tyvaso New Drug Initial Review Pulmonary Arterial Hypertension United Therapeutics
Renvela New Drug Initial Review Phosphate Binder Genzyme
Embeda New Drug Initial Review Narcotic King
Stelara New Drug Initial Review Biologic Response Modifier J&J/Centocor Ortho Biotech
Simponi New Drug Initial Review Biologic Response Modifier Centocor Ortho Biotech
Vivitrol New Drug Initial Review Opioid Antagonist Alkermes
Extavia New Drug Initial Review Multiple Sclerosis Agent Novartis
Zenpep New Drug Initial Review Pancreatic Enzymes Eurand
Lamictal XR New Drug Initial Review Anticonvulsant GlaxoSmithKline
Lamictal ODT New Drug Initial Review Anticonvulsant GlaxoSmithKline
Vyvanse New Drug Appeal Stimulant/ADHD Agent Shire
Bromfed DM New Drug Appeal Non-Narcotic Cough/Cold Morton Grove/Wockhardt
Savella New Drug Appeal SNRI Forest
Nascobal New Drug Appeal Vitamin Strativa
Saphris New Drug Appeal Atypical Antipsychotic Schering-Plough
Moxatag New Drug Appeal Antibiotic MiddleBrook